Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022…
Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022…
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…
VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) — Agra Ventures Ltd. (“AGRA” or the…
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary…
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have…
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT),…
ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company…
CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a…
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic…
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical…
NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a…
– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® (mitapivat) in Sickle Cell…
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023…
Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON,…
Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an…
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March…
DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is…
Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x…
Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations…
BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, with…